Search
forLearn
5 / 801 resultslearn copper tripeptide-1
learn Biotinoyl tripeptide 1
learn GT20029
research compound made to degrade androgen receptors in scalp
learn KY19382
compound that activates Wnt/β-catenin to promote hair regrowth and create new hair follicles
Research
5 / 507 resultsresearch A function for Rac1 in the terminal differentiation and pigmentation of hair
Rac1 is crucial for normal hair structure and pigmentation.
research Rac1 Is Crucial for Hair Follicle Integrity but Is Not Essential for Maintenance of the Epidermis
Rac1 is vital for hair follicle health but not needed for skin maintenance.
research Skin-resident immune cells actively coordinate their distribution with epidermal cells during homeostasis
Skin cells control immune cell placement, helping the skin respond better to challenges.
research Emerging role of ILK and ELMO2 in the integration of adhesion and migration pathways
ILK and ELMO2 help cells move and stick together, important for wound healing and hair growth.
research Epithelial cell migration on laminins
Collagen XVII and CD151 affect cell movement, with CD151 inhibiting migration when bound to integrins.
Community Join
5 / 1000+ resultscommunity IGFBP‐rP1 is a potential therapeutic target in androgenic alopecia
IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.
community GT20029 and PP405 the new fin and min that we been waiting for ?
PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.
community Proof DHT is not the main cause of hair loss. TRPS1 Gene and Protein might be. PP405 won’t work. AMP-303 might!
Hair loss may be linked to the TRPS1 gene and protein, not just DHT. Amplifica's AMP-303 targets mesenchymal stem cells and shows promise in treating hair loss, unlike Pelage's PP405.
community Kintor Pharma Announces Positive Top-line U.S. Phase I Trial Results of GT20029, the World’s First Topical Use PROTAC Compound
The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.
community GT20029. Kintor Pharma’s Product
The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.